Spinout Active LTD

Company profile

Refeyn Ltd

Refeyn - Measuring molecules with light

Our goal is to make mass photometry available to the scientific community. We specialise in label-free single molecule imaging and mass measurement of biomolecules in solution.

CRN
11333643
Founded
2018
Age
8

Overview

Browse spinouts
Legal name
REFEYN LTD
Region
South East England
Registered address
C/O PENNINGTONS MANCHES LLP
9400 GARSINGTON ROAD
OXFORD
ENGLAND
OX4 2HN
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

8 events
10 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

26 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2026

Second Filing Notification Of A Person With Significant Control

Persons-with-significant-control

RP04PSC02 | Transaction MzUxMzUzMDIxMGFkaXF6a2N4 | Paper/PDF filed

Published 01 Apr 2026 22:47

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

15 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MzU2MDk2OGFkaXF6a2N4

Published 15 Nov 2024 12:29

17 Sep
2024

Appoint Person Secretary Company With Name Date

Officers

AP03 | Transaction MzQzNjE5OTk3MGFkaXF6a2N4

Published 17 Sep 2024 11:39

27 Apr
2018

Incorporated

Inception

Company registered at Companies House

Spinout profile

5 entries

Company description

Refeyn develops technology that is capable of measuring and imaging molecular mass.

Refeyn Ltd is a spin-out from the University of Oxford, that employs ~30 people (most in Oxford, but also in the US and Germany) to develop mass photometry and make it available to the research community.

Project impact

The company is new, but has attracted significant recent investment

Refeyn and sold and delivered instruments to labs around the world, with researchers in academia and industry using the instrumentation to perform new science. The company is revenue generating, and has raised significant amount of venture capital funding, and has created a diverse set of jobs.

Refeyn
2018
Refeyn
2018
Refeyn
2018
Refeyn
2018
REFEYN LTD
2018

Public funding

2 awards
First funded
2020
Funded years
2020, 2023
Age at first award
2 years

Projects

2023 Collaborative R&D

Advanced process control of AAV manufacture: digitalisation, PAT and automation to improve productivity, quality and consistency

1 Jun 2023 to 31 May 2025

Awarded
£0
Total cost £0

The therapeutic potential for gene therapies is transformative, where many largely intractable diseases will be treated safely, effectively and durably. Therapies are now starting to get approved (e.g. Roctavian, Zolgensma, and Luxturna), but cost remains a large barrier to entry and widespread patient access, partly due to suboptimal manufacturing proces...

2020 Study Lead participant

Accelerating analytics for gene therapy using enhanced mass photometry

1 Oct 2020 to 30 Sep 2021

Awarded
£177,305
Total cost £253,293

Gene therapy holds huge promise for many conditions that have been difficult to prevent or treat using conventional drugs, including inherited, rare and age-related diseases, and cancers. As the industry grows, there is an urgent need for more efficient, effective technologies for quality control tests. Technologies developed for traditional drugs have ma...

Product types

Collaborative R&D Study